[HTML][HTML] Current management of hepatocellular carcinoma: an Eastern perspective

HJ Yim, SJ Suh, SH Um - World journal of gastroenterology: WJG, 2015 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death, especially in
Eastern areas. With advancements in diagnosis and treatment modalities for HCC, the …

Gemcitabine and antisense-microRNA co-encapsulated PLGA–PEG polymer nanoparticles for hepatocellular carcinoma therapy

R Devulapally, K Foygel, TV Sekar… - … applied materials & …, 2016 - ACS Publications
Hepatocellular carcinoma (HCC) is highly prevalent, and the third most common cause of
cancer-associated deaths worldwide. HCC tumors respond poorly to chemotherapeutic …

Progress in lipid-based nanoparticles for cancer therapy

S Grinberg, C Linder, E Heldman - Critical Reviews™ in …, 2014 - dl.begellhouse.com
Most conventional cancer therapeutics gain limited access to many types of tumors while
having considerable adverse effects, resulting in low therapeutic efficacy and high toxicity …

[HTML][HTML] Targeting PEPT1: a novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy

Y Gong, X Wu, T Wang, J Zhao, X Liu, Z Yao, Q Zhang… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Proton coupled oligopeptide transporter 1 (PEPT1) is a member of the peptide transporter
superfamily and plays important role in the absorption of oligopeptide and peptidomimetic …

Use of nanotechnology in diagnosis and treatment of hepatic fibrosis: A review

S Taymouri, A Taheri - Current Drug Delivery, 2016 - ingentaconnect.com
Liver fibrosis is an important cause of morbidity and mortality worldwide and represent a
difficult clinical challenge of global importance. The liver fibrosis progression needs to be …

化疗药物阿霉素靶向治疗肝癌的研究进展

弓艳霞, 张庆瑜, 唐艳萍 - 中华全科医师杂志, 2016 - cqvip.com
靶向治疗是增加化疗药物疗效并减少其不良反应的重要途径之一, 选择靶向药物载体系统非常
重要. 阿霉素在肝癌的靶向治疗中具有重要作用, 阿霉素载体系统通过不同的作用机制靶向治疗 …